Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase 1/2a Study to Evaluate the Safety, Tolerability, PK and PD of DB-2304 for Injection in Healthy Adult Participants and Participants With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

NCT06625671 is registered in ClinicalTrials.gov with DualityBio Inc. as lead sponsor.

NCT NCT06625671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06625671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase 1/2a Study to Evaluate the Safety, Tolerability, PK and PD of DB-2304 for Injection in Healthy Adult Participants and Participants With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
Lead sponsor
DualityBio Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 4, 2024
Completion date
December 30, 2027
Enrollment
148 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle) or cutaneous lupus erythematosus